Immune Mechanisms in Type 2 Diabetes

Type 2 diabetes is now recognised as a disease at the crossroads of metabolic dysfunction and immune dysregulation. Chronic overnutrition and adiposity foster a state of low-grade inflammation, in which innate immune cells such as macrophages and natural killer cells adopt a pro-inflammatory phenotype. At the same time, adaptive immunity is altered: T-lymphocyte subsets shift towards a Th1-dominant profile and regulatory T-cell numbers decline, exacerbating insulin resistance in adipose tissue, liver and skeletal muscle. Hyperglycaemia further amplifies this vicious cycle by inducing endoplasmic reticulum stress and impairing the anti-inflammatory action of cytokines. Emerging evidence also implicates the gut microbiome and its viral component, the phageome, in triggering immune activation. Collectively, these mechanisms contribute not only to systemic metabolic derangement but also to vascular complications through endothelial dysfunction and aberrant intercellular signalling. A deeper understanding of the precise molecular dialogues between immune mediators and metabolic pathways is paving the way for immunomodulatory strategies alongside established glycaemic control therapies.

Research from Nature Portfolio

Recent work has illuminated a specific impairment in the anti-inflammatory network of type 2 diabetes. In high-glucose conditions, the usual inhibitory effect of interleukin-10 on tumour-necrosis factor secretion by macrophages is markedly diminished. This hyporesponsiveness arises despite preserved receptor expression and involves defective activation of downstream STAT3 signalling. Importantly, pharmacological activation of SHIP1 restores interleukin-10 sensitivity, suggesting that targeting intracellular signalling nodes can reverse immune resistance and ameliorate chronic inflammation in diabetic tissues.

Immune Mechanisms in Type 2 Diabetes publication trend

The graph below shows the total number of articles in immune mechanisms in type 2 diabetes across all publications each year (not limited to Nature Index journals).

Technical terms

Low-grade inflammation: Sustained, mild activation of the immune system characterised by elevated pro-inflammatory cytokines.

Cytokine: Small signalling protein secreted by immune cells to regulate inflammation and cell communication.

Dendritic cell: Antigen-presenting immune cell that captures antigens and activates T lymphocytes.

Interleukin-10 (IL-10): Anti-inflammatory cytokine that limits excessive immune responses and tissue damage.

Single-cell RNA sequencing: Technique that profiles gene expression in individual cells, revealing cellular heterogeneity.

Bacteriophage: Virus that infects bacteria and may influence host immune responses indirectly via microbiome modulation.

Endothelial-to-mesenchymal transition (EndMT): Process by which endothelial cells acquire mesenchymal traits, contributing to vascular dysfunction.

References

1. Hyporesponsiveness to the anti-inflammatory action of interleukin-10 in type 2 diabetes. Scientific Reports (2016).
2. Bacteriophages from treatment-naïve type 2 diabetes individuals drive an inflammatory response in human co-cultures of dendritic cells and T cells. Gut Microbes (2024).
3. Immunometabolic alterations in type 2 diabetes mellitus revealed by single-cell RNA sequencing: insights into subtypes and therapeutic targets. Frontiers in Immunology (2025).
4. Impact of the -1T>C single-nucleotide polymorphism of the CD40 gene on the development of endothelial dysfunction in a pro-diabetic microenvironment. Atherosclerosis (2023).